跳至主要内容
临床试验/NCT03296579
NCT03296579Unknown不适用

A Prospective Open Randomized Clinical Trial of Non-invasive Ventilation Versus Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma.

University of British Columbia0 个研究点目标入组 100 人开始时间: 2018年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
100
主要终点
Time to reach a PRAM score of ≤3

研究概览

简要总结

Acute asthma produces greatly increased work of breathing and increased oxygen requirement secondary to bronchial narrowing and airway obstruction by inflammatory secretions. There is growing evidence that non-invasive ventilation can reverse these processes more efficiently than conventional asthma therapy. Surprisingly, there have not yet been any large scale prospective controlled studies to investigate this hypothesis, (either in adults or children). Consequently, the aim of this study is to determine if the use of non-invasive positive airway pressure, for children admitted to hospital with an acute exacerbation of asthma, reduces their work of breathing, need for adjunctive medications, and shortens the length of hospital stay, compared to current standard therapy.

详细描述

The aim of the study is to determine if the use of NIV, for children admitted to hospital with an acute exacerbation of asthma, reduces their work of breathing, need for adjunctive medication, length of hospital stay, and need for intubation and mechanical ventilation. Study design will be prospective, randomized and controlled. The tightly fitting face mask necessary for NIV makes it impossible to make this a blinded study.

The principal enrollment criteria will be children over 2 years of age presenting to the ER with acute asthma. After diagnosis, all children are treated with standard therapy (systemic steroids plus 3 doses of inhaled salbutamol and 1 dose of inhaled ipratropium over a 1 hour period then hourly salbutamol). The principal decision between discharge track and admission track will be made at 2 hours after first steroid dose. Admission criteria are based on sequential PRAM scores.

After initial asthma treatment and observation in the emergency room, to determine which patients can be discharged home, those who need admission will be asked to join the study, then consented and randomized. There will be three treatment groups:

  • BiPAP: standard steroid dose, hourly salbutamol and BiPAP at 15/5 cm H2O by face mask with rate 10 to 15/min, oxygen as needed.
  • CPAP: standard steroid dose, hourly salbutamol and 8 to 10 cm H2O constant pressure by face mask, oxygen as needed.
  • Conventional therapy: standard steroid dose plus hourly nebulized salbutamol, nebulized ipratropium q 6 hrly, magnesium sulphate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress, oxygen as needed.

All children will be admitted to a small 3 bed respiratory unit. They will be closely monitored and objectively scored every 4 hours using the PRAM asthma clinical severity score (Pediatric Respiratory Assessment Measure). Projected patient enrollment will be at least 30 in each arm. Estimated study duration is 6 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

It is not possible to use non-invasive face masks on the control patients so the study is unblinded.

入排标准

年龄范围
2 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 2-18 years old
  • Clinical diagnosis of acute asthma exacerbation (respiratory rate greater than WHO's age-dependent criteria, a history of similar previous episodes and wheezing heard on auscultation by an experienced physician)
  • PRAM score of 8 or more after 2 hours post-steroid administration
  • Parents willing and able to sign consent
  • Children over the age of 6 willing to provide assent

排除标准

  • Clinical suspicion of bacterial pneumonia: focal crackles or bronchial breathing, and/or major chest x-ray findings.
  • Impending respiratory failure at presentation requiring direct PICU admission
  • Any contraindication to BiPAP use including altered mental status, recent bowel surgery, intractable vomiting, inability to protect airway, pneumothorax.
  • Receiving maintenance dose of oral steroid at time of hospital admission
  • History of serious unrelated illness such as congenital heart disease or bronchopulmonary dysplasia.

研究组 & 干预措施

Conventional asthma therapy.

Active Comparator

Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.

干预措施: Ipratropium (Drug)

Conventional asthma therapy.

Active Comparator

Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.

干预措施: Magnesium Sulfate (Drug)

Conventional asthma therapy.

Active Comparator

Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.

干预措施: Aminophylline (Drug)

Conventional asthma therapy.

Active Comparator

Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.

干预措施: Standard steroid dose, hourly salbutamol, oxygen as needed (Drug)

Non-invasive ventilation (CPAP).

Experimental

Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.

干预措施: CPAP (Device)

Non-invasive ventilation (CPAP).

Experimental

Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.

干预措施: Standard steroid dose, hourly salbutamol, oxygen as needed (Drug)

Non-invasive ventilation (BiPAP)

Experimental

Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.

干预措施: BiPAP (Device)

Non-invasive ventilation (BiPAP)

Experimental

Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.

干预措施: Standard steroid dose, hourly salbutamol, oxygen as needed (Drug)

结局指标

主要结局

Time to reach a PRAM score of ≤3

时间窗: Patients will be followed for the duration of their hospital stay (an estimated average duration of 4 days)

PRAM score includes assessment of oxygen saturations, suprasternal retractions, scalene muscle contraction, air entry and wheezing.

次要结局

  • Time to room air(Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).)
  • Total medication use per 12 hr period(Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).)
  • Numbers failing treatment and transferred to ICU(Patients will be followed for the duration of their hospital stay (an estimated average of 4 days).)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael Seear

Principal Investigator

University of British Columbia

相似试验

Non-invasive Ventilation vs. Standard Therapy for... | 临床试验